Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
366 active trials6 approved drugs33 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,281 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07296666 | Adjuvant Chemotherapy for BTC Based on 3D-PTA | not yet recruiting | Phase 2 | 98 | Fudan UniversityOTHER | 0 | Dec 22, 2025 | clinicaltrials |
| NCT07208526 | A Randomized Trial of Surgical Decision-Making Guided by TDTP-RECIST | not yet recruiting | N/A | 270 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07169916 |
| Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer(YJ-BTC) |
| not yet recruiting |
| N/A |
| 210 |
| Fudan UniversityOTHER |
| 1 |
| Sep 12, 2025 |
| clinicaltrials |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07149558 | Volume-Restricted Resection for Perihilar Cholangiocarcinoma | not yet recruiting | — | 300 | Yongjun ChenOTHER | 0 | Sep 2, 2025 | clinicaltrials |
| NCT07129018 | Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer | not yet recruiting | Phase 2 | 63 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Aug 19, 2025 | clinicaltrials |
| NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma(PEHRICCA) | not yet recruiting | Phase 2 | 49 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT06780553 | Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma(PROFI-CHOL) | not yet recruiting | — | 60 | University Hospital, BordeauxOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT07036185 | A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors | not yet recruiting | Phase 1 | 66 | Shanghai Bao Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07003815 | Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 62 | Tongji HospitalOTHER | 0 | Jun 4, 2025 | clinicaltrials |
| NCT06993025 | Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06919848 | Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06) | not yet recruiting | Phase 2 | 74 | Fudan UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06903273 | Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma(TisGCS for BTC) | not yet recruiting | Phase 2 | 35 | National Cheng-Kung University HospitalOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06818773 | Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer | not yet recruiting | Phase 4 | 35 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Feb 10, 2025 | clinicaltrials |
| NCT06651346 | Cell-Surface Plectin in the Diagnosis of Cholangiocarcinoma from ERCP-directed Biliary Samples | not yet recruiting | — | 100 | University of VirginiaOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06654947 | A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer. | not yet recruiting | Phase 2 | 23 | Fujian Cancer HospitalOTHER_GOV | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06730581 | Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors | not yet recruiting | Phase 2 | 100 | Beijing Biostar Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Dec 12, 2024 | clinicaltrials |
| NCT06699459 | Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC(NICRRBTC) | not yet recruiting | Phase 2 | 76 | Sir Run Run Shaw HospitalOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06670547 | Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography | not yet recruiting | — | 3,000 | Germans Trias i Pujol HospitalOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06662877 | Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment | not yet recruiting | Phase 2 / Phase 3 | 206 | Sun Yat-sen UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06658587 | A Novel Serological Risk Model for Early Non-invasive Diagnosis of Cholangiocarcinoma | not yet recruiting | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06656559 | Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Oct 24, 2024 | clinicaltrials |
| NCT06648525 | Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC | not yet recruiting | Phase 2 | 68 | Harbin Medical UniversityOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT06645067 | Assessment and Modulation of Energy Balance in Cachectic Patients Using Adapted Physical Activity(EMC2APA) | not yet recruiting | — | 10 | University of Rennes 2OTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06567600 | Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma | not yet recruiting | Phase 2 | 43 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT06434493 | Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma(EMPHATIC) | not yet recruiting | N/A | 30 | The Christie NHS Foundation TrustOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06502080 | Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)(RADITOP) | not yet recruiting | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06389500 | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06276153 | Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer(CRGGCext) | not yet recruiting | — | 5,000 | RenJi HospitalOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT05896956 | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | not yet recruiting | — | 500 | RenJi HospitalOTHER | 0 | Jun 9, 2023 | clinicaltrials |
| NCT05644743 | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | not yet recruiting | — | 40 | Chengjun Sui,MDOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT04824742 | Neoadjuvant PDT in the Treatment of Cholangiocarcinoma | not yet recruiting | N/A | 50 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 22, 2025source: clinicaltrials